Take a look at some of the biggest moving agents in the premarket:
Nike (NKE) – Nike came in with 14 cents a share above estimates, with a quarterly profit of 90 cents a share. However, the company’s footwear and athletic clothing revenue came in below analysts’ forecasts, however, and its year-over-year revenue outlook was also shy of estimates. Nike said North American revenues were affected by port issues, which delayed shipments by up to three weeks. Nike shares fell 3.2% in premarket trading.
FedEx (FDX) – FedEx reported quarterly earnings of $ 3.47 per share, exceeding the consensus estimate of $ 3.23 per share. Revenues also exceeded expectations. FedEx’s average package revenue for ground service has increased by 11% as it continues to benefit from the growing pandemic in e-commerce orders. Its shares increased by 4% in the premarket share.
Skillz (SKLZ) – Skillz fell 7% in its premarket share after the mobile gaming company announced a public offering of 32 million shares. Offering a price of $ 24 per share, Skillz sold 17 million shares and some shareholders sold the rest. Skillz said he would use the company’s revenue for general purposes.
AstraZeneca (AZN) – The AstraZeneca Covid-19 vaccine has received support from regulator Canada Health Canada, which has joined European countries in saying the vaccine is not linked to an increase in blood clots. Countries that have temporarily stopped using the vaccine have resumed vaccination.
Hartford Financial (HIG) – The financial services company said it was “carefully considering” a takeover bid by insurance company Chubb (CB) for $ 65 per share or more than $ 23 billion. Shares of Hartford rose 18.7% on Thursday after the offer was announced, although it accounts for about 1.4% of premarket trading.
Ollie’s Bargain Outlet (OLLI) – Ollie’s beats are estimated at 14 cents per share, with quarterly earnings of 97 cents per share. Discounted retailers’ revenues also exceeded Wall Street forecasts. Sales at comparable stores increased by 8.8%, exceeding the consensus forecast of FactSet by an increase of 3.2%. Ollie’s shares gained 4.6% in premarket trading.
Enphase (ENPH), SolarEdge Technologies (SEDG) – Susquehanna Financial upgraded both alternative energy stocks to “positive” from “neutral” based on an anticipated expansion of solar installations in the coming years and the strength of the two residential companies . Enphase grew 3.3% in the premarket, while SolarEdge gained 2.1%.
Ford Motor (F) – Ford shares rose 2.5% in premarket trading after Barclays upgraded its share to “overweight” from “equal weight” and raised its target price per share to $ 16 per share from $ 9. Barclays is encouraged by Ford’s electric vehicle development strategy, among other factors.
Coherent (COHR) – The laser technology company remains vigilant as it analyzes competing takeover bids from Lumentum (LITE) and II-VI (IIVI). Coherent first entered into an agreement to be acquired by Lumentum in January, but received eight subsequent bids and revised bids since then.
Molson Coors (TAP) – the brewer’s stock fell 2.3% in premarket stock after Deutsche Bank added it to its list of “short-term sales catalysts”. Deutsche Bank said the call was based on short-term concerns, including a significant impact on first-quarter results due to bad weather in February in Texas.
Petco Health (WOOF) – The pet retailer has been upgraded to “buy” from “neutral” at Bank of America Securities, saying Petco’s fourth-quarter and 2021 results are ahead of its expectations. The stock rose 2.8% in premarket trading after losing 3.8% in Thursday’s trading.
Hims & Hers Health (HIMS) – Hims & Hers Health shares fell 3.3% in the premarket after the telehealth company reported a quarterly net loss of $ 3.1 million, even though it was less than the loss of $ 12.4 million reported a year earlier. However, revenues have grown more than expected and total revenues have increased by 80% by 2020.
Sarepta Therapeutics (SRPT) – The shares of the drug manufacturer gathered 5.4% in premarket trading after reporting optimistic results in a study involving an experimental treatment of muscular dystrophy.